<DOC>
	<DOCNO>NCT00929851</DOCNO>
	<brief_summary>48-week , 2-arm parallel group , `` fix combination '' beclomethasone dipropionate plus formoterol fumarate versus formoterol patient severe chronic obstructive pulmonary disease</brief_summary>
	<brief_title>BDP/FF Versus Formoterol Fumarate ( FF ) Patients With Severe COPD ( Lung Function Exacerbation Rate )</brief_title>
	<detailed_description>48-week , double blind , randomize , multinational , multicentre , 2-arm parallel group , reference treatment control clinical trial `` fixed combination '' beclomethasone dipropionate plus formoterol fumarate versus formoterol patient severe chronic obstructive pulmonary disease</detailed_description>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Formoterol Fumarate</mesh_term>
	<mesh_term>Beclomethasone</mesh_term>
	<criteria>Severe COPD At least one COPd exacerbation previous year Asthma , allergic rhinitis atopic disease Unstable concurrent disease : Evidence heart failure</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>